Evidence map›Paper›PMID 41209372›Full record

ArticleOpen forum infectious diseases2025

Long-acting Cabotegravir/Rilpivirine for Treatment of HIV During Pregnancy: A Case Series.

Shawnalyn W Sunagawa, Carly Cloud Floyd, Sara H Bares, Anthony T Podany, Kimberly K Scarsi, Timothy Mykris, Lee Winchester, Jennifer O'Neill, Maureen Kubat, Christine Tran and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shawnalyn W SunagawaDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID https://orcid.org/0009-0005-3068-3732
Carly Cloud FloydDepartment of Pharmacy Practice and Science, College of Pharmacy, University of New Mexico, Albuquerque, New Mexico, USA.ORCID https://orcid.org/0000-0001-9316-5610
Sara H BaresDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0002-2130-2505
Anthony T PodanyDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Kimberly K ScarsiDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Timothy MykrisAntiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Lee WinchesterAntiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Jennifer O'NeillDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Maureen KubatDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Christine TranDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Jennifer M DavisDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0002-4971-1490
Jeremy W SnyderDivision of General Internal Medicine, Department of Internal Medicine, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA.ORCID https://orcid.org/0009-0004-0693-5971
Joshua P HavensDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0001-9894-615X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present pharmacokinetic data on long-acting cabotegravir/rilpivirine (LA CAB/RPV) from two patients during their second and third trimesters. Monthly LA CAB/RPV dosing maintained concentrations above the proposed efficacy thresholds while bimonthly dosing resulted in subtherapeutic RPV concentrations. This highlights the potential of monthly LA CAB/RPV dosing in pregnancy.

Indexed as

HIVlong-acting cabotegravir/rilpivirinepregnancy

Identifiers

PMID41209372
PMCPMC12596122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.